Assessments of Health Utilities in Patients With Metabolic Dysfunction-Associated Steatohepatitis: Cross-Walk Between Disease-Specific Chronic Liver Disease Questionnaire, Short Form SF-6D, and EuroQol EQ-5D Instruments

Gastro hep advances Pub Date : 2025-01-01 DOI:10.1016/j.gastha.2025.100642

Zobair M. Younossi , Maria Stepanova , Yestle Kim , Stephen Dodge , Dominic Labriola , Rebecca Taub , Fatema Nader

{"title":"Assessments of Health Utilities in Patients With Metabolic Dysfunction-Associated Steatohepatitis: Cross-Walk Between Disease-Specific Chronic Liver Disease Questionnaire, Short Form SF-6D, and EuroQol EQ-5D Instruments","authors":"Zobair M. Younossi , Maria Stepanova , Yestle Kim , Stephen Dodge , Dominic Labriola , Rebecca Taub , Fatema Nader","doi":"10.1016/j.gastha.2025.100642","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and Aims</h3><div>The EuroQol-5D (EQ-5D) is a commonly used measure of health utilities to calculate quality-adjusted life years. For the clinical trials that use Chronic Liver Disease Questionnaire-nonalcoholic fatty liver disease (CLDQ-NAFLD) or Short Form-36 (SF-36), ability to convert the health-related quality of life scores (CLDQ-NAFLD or SF-36) to EQ-5D scores provides a valuable method to estimate health utility.</div></div><div><h3>Methods</h3><div>Baseline data of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) patients were used in this study. We used 2 cross-walk algorithms to estimate EQ-5D scores. The first algorithm used 6 domains of CLDQ-NAFLD in a fractional logistic model to yield EQ-5D estimates. The other algorithm included calculation of SF-6D utility scores from SF-36 items, which were fed into a regression model that estimated EQ-5D scores from SF-6D scores.</div></div><div><h3>Results</h3><div>There were 883 MASH patients with CLDQ-NAFLD and SF-36 data: 25% ≥65 years, 44% male, 80% obese (body mass index >30), 67% type 2 diabetes, 62% F3 fibrosis, and 38% F1B/F2 fibrosis. The mean estimated EQ-5D scores were 0.851 (standard deviation = 0.146) according to CLDQ-NAFLD-based algorithm and 0.853 (standard deviation = 0.097) according to the SF-36-based algorithm. The correlations between the 2 estimated EQ-5D scores were up to +0.74. Similar to the total sample, the differences between the mean EQ-5D estimates using either calculation method did not exceed 0.012 in all studied subgroups (by age, sex, obesity, type 2 diabetes, and fibrosis stage).</div></div><div><h3>Conclusion</h3><div>Both cross-walk algorithms for the calculation of the EQ-5D utility scores in MASH patients were estimable with CLDQ-NAFLD or SF-36 instruments. A high positive correlation was seen between the total score and subgroup estimates using either method.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 6","pages":"Article 100642"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastro hep advances","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772572325000299","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background and Aims

The EuroQol-5D (EQ-5D) is a commonly used measure of health utilities to calculate quality-adjusted life years. For the clinical trials that use Chronic Liver Disease Questionnaire-nonalcoholic fatty liver disease (CLDQ-NAFLD) or Short Form-36 (SF-36), ability to convert the health-related quality of life scores (CLDQ-NAFLD or SF-36) to EQ-5D scores provides a valuable method to estimate health utility.

Methods

Baseline data of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) patients were used in this study. We used 2 cross-walk algorithms to estimate EQ-5D scores. The first algorithm used 6 domains of CLDQ-NAFLD in a fractional logistic model to yield EQ-5D estimates. The other algorithm included calculation of SF-6D utility scores from SF-36 items, which were fed into a regression model that estimated EQ-5D scores from SF-6D scores.

Results

There were 883 MASH patients with CLDQ-NAFLD and SF-36 data: 25% ≥65 years, 44% male, 80% obese (body mass index >30), 67% type 2 diabetes, 62% F3 fibrosis, and 38% F1B/F2 fibrosis. The mean estimated EQ-5D scores were 0.851 (standard deviation = 0.146) according to CLDQ-NAFLD-based algorithm and 0.853 (standard deviation = 0.097) according to the SF-36-based algorithm. The correlations between the 2 estimated EQ-5D scores were up to +0.74. Similar to the total sample, the differences between the mean EQ-5D estimates using either calculation method did not exceed 0.012 in all studied subgroups (by age, sex, obesity, type 2 diabetes, and fibrosis stage).

Conclusion

Both cross-walk algorithms for the calculation of the EQ-5D utility scores in MASH patients were estimable with CLDQ-NAFLD or SF-36 instruments. A high positive correlation was seen between the total score and subgroup estimates using either method.

查看原文本刊更多论文

代谢功能障碍相关脂肪性肝炎患者的健康效用评估：疾病特异性慢性肝病问卷，SF-6D短表格和EuroQol EQ-5D仪器之间的交叉行走

背景和目的EuroQol-5D （EQ-5D）是一种常用的健康效用测量方法，用于计算质量调整生命年。对于使用慢性肝病问卷-非酒精性脂肪性肝病（CLDQ-NAFLD）或短表格-36 （SF-36）的临床试验，将健康相关生活质量评分（CLDQ-NAFLD或SF-36）转换为EQ-5D评分的能力提供了一种评估健康效用的有价值的方法。方法：本研究使用非肝硬化代谢功能障碍相关脂肪性肝炎（MASH）患者的基线数据。我们使用两种交叉行走算法来估计EQ-5D分数。第一种算法在分数逻辑模型中使用CLDQ-NAFLD的6个域来产生EQ-5D估计。另一种算法包括从SF-36项目中计算SF-6D效用得分，并将其输入回归模型，根据SF-6D得分估计EQ-5D得分。结果883例MASH患者合并CLDQ-NAFLD和SF-36数据：25%≥65岁，44%男性，80%肥胖（体重指数为30），67% 2型糖尿病，62% F3纤维化，38% F1B/F2纤维化。基于cldq - nafld算法的EQ-5D评分均值为0.851（标准差= 0.146），基于sf -36算法的EQ-5D评分均值为0.853（标准差= 0.097）。两种估计EQ-5D评分之间的相关性高达+0.74。与总样本相似，在所有研究亚组（按年龄、性别、肥胖、2型糖尿病和纤维化分期）中，使用两种计算方法的平均EQ-5D估计值之间的差异不超过0.012。结论使用CLDQ-NAFLD或SF-36仪器计算MASH患者EQ-5D效用评分的两种交叉行走算法均可评估。使用任何一种方法，总分和亚组估计值之间都存在高度正相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊